ADCC, CDC and ADCP assays are relatively complex experiments, and many factors play roles to determine the success of the assay, including:

1. Target molecule expression level on the target cell surface;
2. Binding affinity of the antibody drug with the target molecule;
3. The antibody drug IgG subclass;
4. Potential effector function blockade mechanism on the target cell;
5. Binding epitope on the target molecule for the antibody drug.

We will thoroughly evaluate your project and make our way to counter potential project risks to the largest extent. Our delivery standard, deliverables and project turnaround time are as follows:

Please download our quotation form, fill it carefully and send it to us at [email protected] for a free project evaluation.

ADCC Assay

There are two formats of ADCC assays at in vitro bioassay platform:

ADCC Service Key Features:

• Published and functionally validated benchmarks are freely available
• Large target cell collection comprising of >200 tumor cell lines and >100 target-overexpressing cell lines
• Human PBMCs with proven ADCC function are available with ethics approval
• ADCC reporter assay is well developed and validated
• A highly professional and skilled team with extensive IND-filing experiences
• Assay instruments are IQ, OQ and PQ-certified with audit trails
• Established assays are available for CD20, Her2, CD38, EGFR, PD-L1, mTNFα, B7H3, Claudin 6 and Claudin 18.2, etc

Case Study

• 

  Case 1: Rituximab mediates ADCC effect in a dose-dependent format. Primary human PBMCs and Raji cells are used as the effector and target cells

• 

  Case 2: Anti-Claudin 18.2 antibody mediates ADCC effect in a dose-dependent format. ADCC reporter cells and human Claudin 18.2 overexpressing cells are used as the effector and target cells.

CDC assay

¹ A large collection of target-overexpressing cell lines is freely available

² Pooled normal human serum (PNHS) and normal human serum complement protein (NHSC) have comparable effector functions in our CDC assays

CDC Service Features

• Published and functionally validated benchmarks are freely available
• Large target cell collection comprising of >200 tumor cell lines and >100 target-overexpressing cell lines
• Suitable for mouse antibodies
• A highly professional and skilled team with extensive INDfiling experiences
• Assay instruments are IQ, OQ and PQ-certified with audit trails
• Established assays are available for CD20, Her2, CD38, EGFR, PD-L1, mTNFα, B7H3, Claudin 6 and Claudin 18.2, etc

Case Study

• 

  Case 1: Adalimumab mediated CDC dose response curves. mTNFα overexpressing cells are used as the target cells, and PNHS (blue) or NHSC(red) are effector molecules.

• 

  Case 2: Rituximab mediated CDC dose response curves. Raji cells are used as the target cells, and PNHS (blue) or NHSC (red) are effector molecules.

ADCP Assay

¹ Macrophages can be differentiated into M1 or M2 type
² ProBio has a large collection of target-overexpressing cell lines, which are freely available to our clients
³ Early screening refers to the antibody drug discovery stage prior to humanization

ADCP Service Features

• Extensive experience from more than a hundred of projects
• Therapeutic antibody positive controls* for popular targets are freely available
• Stringent QC criteria during macrophage differentiation and maturation
• Fully validated ADCP reporter gene assay method is available
• Stringent documentation system that meets the requirement of IND-filing

*CD20, CD38, CD47/SIRPα and Claudin 18.2, etc

Case Study

ADCP assay detection:

Two distinct fluorescence dyes are used to label the target cells and the effector cells, respectively. The population of Q2 quadrant which showing double positive is the group of target cells consuming by phagocytosis. The macrophage phagocytosis percentage is calculated as Q2/(Q2+Q3)*100%.

• 

  Without antibody

• 

  With antibody

• 

  SampleA(Conc.μg/mL)